Comparison of mucus and serum biomarker sampling in chronic rhinosinusitis with nasal polyps.
biomarker
chronic rhinosinusitis
eosinophilic rhinitis
nasal polyposis
Journal
International forum of allergy & rhinology
ISSN: 2042-6984
Titre abrégé: Int Forum Allergy Rhinol
Pays: United States
ID NLM: 101550261
Informations de publication
Date de publication:
22 Nov 2023
22 Nov 2023
Historique:
revised:
12
08
2023
received:
10
04
2023
accepted:
14
09
2023
medline:
22
11
2023
pubmed:
22
11
2023
entrez:
22
11
2023
Statut:
aheadofprint
Résumé
The objective of this study was to analyze advantages and disadvantages of mucus and serum for biomarker analysis. This study includes prospective study of 61 CRS with nasal polyps patients who were followed over 24 months and over nine time points after functional endoscopic sinus surgery. At each time points, the nasal polyp score (NPS) was assessed and mucus as well as serum was collected. Selected were measured in mucus and serum. Mean, standard deviation and variance, undetectable values, and the correlation of the biomarkers to the NPS over time and to early recurrences were calculated, and the effect of surgery on the biomarkers was assessed. Additionally, the diurnal rhythm of all biomarkers was measures in order to assure stable biomarker values during sampling times. All biomarkers showed stable values during sampling times. Serum biomarker levels displayed higher percentages of undetectable values compared to mucus biomarkers. Mucus periostin (p < 0.001, r = 0.89), mucus IgE (p < 0.001, r = 0.51), serum periostin (p < 0.001, r = 0.53), mucus CST1 (p < 0.001, r = 0.27), and serum IgE (p < 0.01, r = -0.18) were the best marker and medium combinations to track the NPS over time and to predict recurrences. Mucus serpinF2 was negatively correlated and predicted early recurrences (p = 0.026, R Serum and mucus both represent viable mediums for "liquid biopsies." The most promising biomarker/medium combinations over time to track disease severity were mucus periostin, mucus IgE, serum periostin, mucus CST1, and serum IgE. Mucus serpinF2 was the best biomarker to predict early recurrences.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Merck
ID : NCT04915456
Informations de copyright
© 2023 The Authors. International Forum of Allergy & Rhinology published by Wiley Periodicals LLC on behalf of American Academy of Otolaryngic Allergy and American Rhinologic Society.
Références
Fokkens WJ. European position paper on rhinosinusitis and nasal polyps 2020. Rhinology. 2020;58:1-464.
De Greve G, Hellings PW, Fokkens WJ, Pugin B, Steelant B, Seys SF. Endotype-driven treatment in chronic upper airway diseases. Clin Transl Allergy. 2017;7:2.
Rudmik L. Economics of chronic rhinosinusitis. Curr. Allergy Asthma Rep. 2017;17:20.
Soler Z, Wittenberg E, Schlosser R, Mace J, Smith T. Health state utility values in patients undergoing endoscopic sinus surgery. Laryngoscope. 2011;121:2672-2678.
Gliklich RE, Metson R. Effect of sinus surgery on quality of life. Otolaryngol Head Neck Surg. 1997;117:12-17.
Ye Z, Sun L, Wang Q. A head-to-head comparison of EQ-5D-5 L and SF-6D in Chinese patients with low back pain. Heal. Qual Life Outcomes. 2019;17:57.
Mueller SK, Nocera AL, Dillon ST, et al. Non-invasive exosomal proteomic biosignatures including cystatin-SN (CST 1), peroxiredoxin-5 (PRDX5) and glycoprotein-VI (GP6) accurately predict chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2019;9:177-186.
Mueller SK, Wendler O, Nocera A. et al. Escalation in mucus cystatin 2, pappalysin-A and periostin levels over time predict need for recurrent surgery in CRSwNP. Int. Forum Allergy Rhinol. 2019;9:1212-1219.
Tomassen P, Vandeplas G, Van Zele T, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J. Allergy Clin. Immunol. 2016;137:1449-1456.e4.
Miyake MM, Workman AD, Nocera AL, et al. Discriminant analysis followed by unsupervised cluster analysis including exosomal cystatins predict presence of chronic rhinosinusitis, phenotype, and disease severity. Int. Forum Allergy Rhinol. 2019;9:1069-1076.
Soler ZM, Schlosser RJ, Bodner TE, et al. Endotyping chronic rhinosinusitis based on olfactory cleft mucus biomarkers. J. Allergy Clin. Immunol. 147:P1732-P1741. https://doi.org/10.1016/j.jaci.2021.01.021
Grayson J, Hopkins C, Mori E, Senior B, Harvey R. Contemporary classification of chronic rhinosinusitis beyond polyps vs no polyps: a review. JAMA Otolaryngol Head Neck Surg. 2020;146:831-838.
Mueller SK, Wendler O, Nocera A, et al. Escalation in mucus cystatin 2, pappalysin-A, and periostin levels over time predict need for recurrent surgery in chronic rhinosinusitis with nasal polyps. Int. Forum Allergy Rhinol. 2019;9:1212-1219.
Mueller S, Nocera AL, Dillon ST, Libermann TA, Wendler O, Bleier BS. Tissue and exosomal serine protease inhibitors are significantly overexpressed in chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy. 2019;33(4):359-368.
Mueller SK, Nocera AL, Workman A, et al. Significant polyomic and functional upregulation of the PAPP-A/IGFBP-4/5/IGF-1 axis in chronic rhinosinusitis with nasal polyps. Int. Forum Allergy Rhinol. 2020;10:546-555.
Mueller S, Nocera AL, Dillon ST, Wu D, Libermann TA, Bleier BS. Highly multiplexed proteomic analysis reveals significant tissue and exosomal coagulation pathway derangement in chronic rhinosinusitis with nasal polyps. Int Forum Allergy Rhinol. 2018;8(12):1438-1444.
Miyake MM, Workman AD, Nocera AL, et al. Exosomal cystatins predict chronic rhinosinusitis, phenotype, and disease severity. Int. Forum Allergy Rhinol. 2019;143:1525-1535.
Maxfield AZ, Landegger LD, Brook CD, et al. Periostin as a biomarker for nasal polyps in chronic rhinosinusitis. Otolaryngol Head Neck Surg. 2018;158:181-186.
Watelet JB, Bachert C, Claeys C, Van Cauwenberge P. Matrix metalloproteinases MMP-7, MMP-9 and their tissue inhibitor TIMP-1: expression in chronic sinusitis vs nasal polyposis. Allergy. 2004;59(1):54-60.
Miyake MM, Workman AD, Nocera AL, et al. Discriminant analysis followed by unsupervised cluster analysis including exosomal cystatins predict presence of chronic rhinosinusitis, phenotype, and disease severity. Int Forum Allergy Rhinol. 2019;9:1069-1076.
Yan B, Lou H, Wang Y, et al. Epithelium-derived cystatin SN enhances eosinophil activation and infiltration through IL-5 in patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2019;144:455-469.
Fukuoka A, Matsushita K, Morikawa T, et al. Human cystatin SN is an endogenous protease inhibitor that prevents allergic rhinitis. J Allergy Clin Immunol. 2018;143:1153-1162.
Conway SJ, Izuhara K, Kudo Y, et al. The role of periostin in tissue remodeling across health and disease. Cell. Mol. Life Sci. 2014;71:1279-1288.
Greenlee KJ, Corry DB, Engler DA, et al. Proteomic identification of in vivo substrates for matrix metalloproteinases 2 and 9 reveals a mechanism for resolution of inflammation. J Immunol. 2006;177:7312-7321.
Chen X, Chang L, Li X, et al. Tc17/IL-17A up-regulated the expression of MMP-9 via NF-kappaB pathway in nasal epithelial cells of patients with chronic rhinosinusitis. Front Immunol. 2018;19:2121.
Galli S, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012;18:693-704.
Xu M, Zhang W, Chen D, Zhou H, Chen L. Diagnostic significance of serum periostin in eosinophilic chronic sinusitis with nasal polyps. Acta Otolaryngol. 2018;138:387-391.
Mueller SK, Wendler O, Mayr S, et al. Effect of postoperative systemic prednisolone on short-term and long-term outcomes in chronic rhinosinusitis with nasal polyps: a multi-centered randomized clinical trial. Front Immunol. 2023;14:1075066.
Hernandez AK, Wendler O, Mayr S, Iro H, Hummel T, Mueller SK. Predictors of olfactory improvement after endoscopic sinus surgery in chronic rhinosinusitis with nasal polyps. J Laryngol Otol. 2023;137:524-531.
Schafer D, Schmid M, Gode U, Baenkler H. Dynamics of eicosanoids in peripheral blood cells during bronchial provocation in aspirin-intolerant asthmatics. Eur. Respir. J. 1999;13:638-646.
Stewart A, Hays R, Ware JJ. The MOS short-form general health survey. Reliability and validity in a patient population. Med Care. 1988;26:724-735.
Stewart A, Greenfield S, Hays R, Al E. Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. JAMA. 1989;262:907-913.
Clogg CC, Petkova E, Haritou A. Statistical methods for comparing regression coefficients between models. Am J Sociol. 1995;100(5):1261-1293.
Paternoster R, Brame R, Mazerolle P, Piquero A. Using the correct statistical test for equality of regression coefficients. Criminology. 1998;36:859-866.
Takahashi K, Meguro K, Kawashima H, et al. Serum periostin levels serve as a biomarker for both eosinophilic airway inflammation and fixed airflow limitation in well-controlled asthmatics. J Asthma. 2019;56:236-243.
Mueller S. The role of exosomes in the pathophysiology of chronic rhinosinusitis. Front Cell Infect Microbiol. 2022;11:812920.
Mueller SK, Nocera AL, Workman A et al. Significant polyomic and functional upregulation of the PAPP-A/IGFBP/IGF axis in CRSwNP. Int Forum Allergy Rhinol. 2020;10:546-555.
Lucas B, Voegels R, do Amaral J, Bachi A, Pezato R. BMP-7, MMP-9 and TGF-β tissue remodeling proteins and their correlations with interleukins 6 and 10 in chronic rhinosinusitis. Eur Arch Otorhinolaryngol. 2021;278:4335-4343.
Fokkens WJ, Lund V, Bachert C, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74:2312-2319.